Senexis Ltd.
Executive Summary
Senexis Ltd. was formed in November 2002 to develop novel therapeutics and diagnostics for currently incurable aging-related disorders such as Alzheimer's disease, Parkinson's disease and type 2 diabetes. Senexis has identified a novel mechanism for inhibiting amyloidosis, the abnormal clumping together of proteins or peptides in the brain or body to form toxic protein bundles thought to damage and destroy cells associated with Senexis' target diseases.